Azitra, Inc. (AZTR): Cash & Equivalents
$2.07M
As of 2025-12-31
$6.73M
As of 2026-06-30
-16.0%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.07M | -54.6% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $4.55M | +153.6% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $1.80M | -48.6% | 2025-02-24, Balance as of period end |
| 2022-12-31 | $3.49M | n/a | 2024-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Azitra, Inc. (AZTR) | 2025-12-31 | $2.07M | -54.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare AZTR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗